Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone with Nab-Paclitaxel for GR+ TNBC
NCT02788981Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Mar 2017
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Nab-Paclitaxel + Mifepristone with Nab-Paclitaxel + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 12 months. Started Mar 2017; status: active, not recruiting.
02
Drugs
mifepristone
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02788981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788981.